The expression of prostate-specific antigen in invasive breast carcinoma and its relationship with routine clinicopathologic parameters

Abstract

Background:Invasive breast carcinoma is one of the most common cancers of women. Parameters such as lymph node status, tumor grade, and the status of hormone receptors are among the main prognostic determinants of this cancer. Immunohistochemical detection of prostate-specific antigen (PSA) is widely used to identify metastatic prostatic adenocarcinoma. However, its immunoreactivity has been found in some non-prostatic tissues. This study was conducted to assess PSA expression in invasive breast carcinoma and its relationship with routine clinicopathologic parameters.Materials and Methods:100 formalin-fixed and paraffin-embedded invasive breast carcinoma tissue specimens from the pathology archive of Alzahra hospital (Isfahan, Iran) were studied for the expression of estrogen receptor (ER), progesterone receptor (PR), HER2/neu, and PSA by immunohistochemistry. Stained sections were classified according to the intensity of staining and the percentage of cells showing PSA staining. The relationship between PSA expression and other markers, age, lymph node status, tumor subtype, and tumor grade was then studied.Results:No association was found between PSA expression on one hand and PR, Her2/neu, age, lymph node status, tumor grade, and tumor subtype on the other. PSA score was reversely correlated with ER expression (P = 0.015).Conclusion:Despite the reverse relationship between PSA expression and the immunoreactivity of ER, PSA expression was not correlated with other prognostic factors. Therefore, the detection of PSA by immunohistochemistry does not seem to be a significant prognostic parameter in patients with invasive breast carcinoma.

Light Emitting Diode (LED) Phototherapy versus Conventional Phototherapy in Neonatal Hyperbilirubinemia: A Single Blinded Randomized Control Trial from Coastal India

“…Sherbiny HS et al [17] documented high intensity LED phototherapy to be better in comparison to intensive conventional phototherapy. However, on the contrary, studies by Mohammadizadeh M et al (blue fluorescent phototherapy versus LED) [7], Takcı S et al (intensive conventional and intensive LED phototherapy) [8], and ViauColindres J et al [18] have concluded that there is no significant difference in rate of decrease in serum bilirubin levels between LED and conventional phototherapy group, since they all had compared between different intensive phototherapy units with matched irradiances as per criteria of American Academy of Pediatrics [11]. In studies by Seidman DS et al [19, 20] there was no significant difference between phototherapy interventions by blue green LED versus Blue LED versus conventional phototherapy.…”

Current Approaches, Challenges and Future Directions for Monitoring Treatment Response in Prostate Cancer

“…PSA immunoreactivity has been found in some non-prostatic tissues in small amounts such as parotid gland, apocrine glands of the skin, bladder, ovary, pancreatic tissues and breast 82 - 85 . In fact, efforts have been made to investigate PSA utilization as a marker of breast cancer but with little success 85 . Diagnostic dilemmas have been reported in the setting of treated prostate cancer and the development of a parotid oncocytoma.…”

The Potentiality of Prostate-Specific Antigen as a Prognostic Biomarker in Breast Cancer

“…Evidence exists suggesting its expression in both invasive and noninvasive breast cancers, and this expression might vary based on the histological subtype. Prior research has revealed an inconclusive association between PSA and ER, androgen receptors (AR), and/or the human epidermal growth factor 2 (HER-2) [ 7 - 9 ]. PSA is a non-tissue-specific protein and has been found in a variety of female tissues and body fluids.…”